Table 3.
Demographic, clinical characteristics and neurocognitive performances among CHR converters, non-remitted CHR and remitted CHR subjects.
| CHR converters |
Non-remitted CHR |
Remitted CHR |
Statistical significance |
|
|---|---|---|---|---|
| Samples completed the P300 oddball paradigm | ||||
| Cases | 19 | 32 | 53 | / |
| Age (years) | 19.7±5.3 | 18.7±5.16 | 18.0±4.5 | F(2,101)=0.86, p=0.43 |
| Gender (M/F) | 12/7 | 17/15 | 26/27 | X2=1.12, p=0.57 |
| Education | 10.8±2.5 | 10.4±3.1 | 10.4±2.7 | F(2,101)=0.15, p=0.86 |
| IQ | 95.5±13.2 | 103.3±13.2 | 101.0±11.1 | F(2,87)=2..00, p=0.14 |
| DUP (months) | 4.4±3.9 | 5.2±4.0 | 6.2±4.5 | F(2,101)=1.44, p=0.24 |
| Medicated | 7/19 | 4/19 | 8/19 | / |
| SOPS_P | 9.7±3.0 | 10.2±3.4 | 9.4±3.4 | F(2,101)=0.56, p=0.57 |
| SOPS_N | 13.11±6.5 | 11.5±5.7 | 10.9±5.6 | F(2,101)=1.02, p=0.37 |
| SOPS_D | 6.9±3.3 | 6.2±3.0 | 6.7±2.8 | F(2,101)=0.46, p=0.63 |
| SOPS_G | 8.2±3.5 | 9.8±2.6 | 8.7±3.2 | F(2,101)=2.01, p=0.14 |
| Highest GAF | 77.5±2.2 | 77.8±3.3 | 76.9±6.1 | F(2,101)=1.25, p=0.29 |
| Current GAF | 53.1±8.1 | 53.5±2.6 | 55.7±8.0 | F(2,101)=0.42, p=0.66 |
| SoP_T | 53.1±9.1 | 55.5±7.3 | 56.7±7.4 | F(2,93)=1.31, p=0.27 |
| AV_T | 47.2±11.6 | 51.0±9.7 | 51.9±8.0 | F(2,93)=1.58, p=0.21 |
| WM_T | 45.3±10.0 | 48.2±8.9 | 44.8±8.1 | F(2,93)=1.48, p=0.23 |
| Samples completed the P300 novel paradigm | ||||
| Cases | 23 | 40 | 68 | / |
| Age (years) | 19.7±5.5 | 18.3±5.0 | 18.8±5.1 | F(2,128)=0.57, p=0.57 |
| Gender (M/F) | 14/9 | 21/19 | 32/36 | X2=1.35, p=0.51 |
| Education | 10.5±2.8 | 10.3±3.0 | 10.6±2.9 | F(2,128)=0.14, p=0.87 |
| IQ | 91.9±18.9 | 100.7±14.0 | 99.1±11.8 | F(2,110)=2.46, p=0.09 |
| DUP (months) | 5.5±5.2 | 5.0±4.2 | 5.5±4.0 | F(2,128)=0.15, p=0.86 |
| Medicated | 7/21 | 4/21 | 10/21 | / |
| SOPS_P | 9.8±3.1 | 10.5±3.2 | 9.3±3.5 | F(2,128)=1.59, p=0.21 |
| SOPS_N | 13.3±6.2 | 11.1±5.5 | 11.3±6.0 | F(2,128)=1.14, p=9.32 |
| SOPS_D | 6.8±3.2 | 6.4±3.1 | 6.7±3.3 | F(2,128)=0.12, p=0.89 |
| SOPS_G | 8.2±3.2 | 9.4±2.6 | 8.8±3.3 | F(2,128)=1.27, p=0.29 |
| Highest GAF | 77.4±2.5 | 78.1±3.3 | 77.0±5.9 | F(2,128)=0.45, p=0.64 |
| Current GAF | 51.9±7.6 | 53.9±6.4 | 53.6±9.6 | F(2,128)=0.66, p=0.52 |
| SoP_T | 51.3±10.2 | 54.0±7.6 | 54.7±7.2 | F(2,119)=1.37, p=0.26 |
| AV_T | 45.5±11.4 | 49.9±8.8 | 51.7±9.2 | F(2,119)=3.20, p<0.05 |
| WM_T | 42.6±8.5 | 45.8±9.9 | 44.8±10.4 | F(2,119)=0.66, p=0.52 |
In samples who completed the P300 oddball paradigm, 16 CHR converters, 31 non-remitted CHR and 49 remitted CHR completed MCCB tests; In samples who completed the P300 novel paradigm, 19 CHR converters, 38 non-remitted CHR and 65 remitted CHR completed MCCB tests.